Breast cancer risks and risk prediction models

Breast Care

Volumn 10, Issue 1, 2015, Pages 7-12

  Engel, Christoph ^a   Fischer, Christine ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; Hereditary cancer risk; Ovarian cancer; Risk prediction models

Indexed keywords

BRCA1 PROTEIN;

BREAST CANCER; CANCER RISK; CLINICAL PRACTICE; COMPUTER PROGRAM; FAMILY COUNSELING; FAMILY HISTORY; GENE MUTATION; GENETIC RISK; HUMAN; INHERITANCE; KNOWLEDGE; MAJOR GENE; MEDICAL DECISION MAKING; NONBIOLOGICAL MODEL; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK PREDICTION MODEL;

EID: 84926334671     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000376600     Document Type: Review

References (65)

1. Antoniou A, Pharoah PD, Narod S, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
2. Begg CB, Haile RW, Borg A, et al.: Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008;299: 194-201.
3. Brose MS, Rebbeck TR, Calzone KA, et al.: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94: 1365-1372.
4. Chen S, Iversen ES, Friebel T, et al.: Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-871.
5. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56:265-271.
6. Easton DF, Steele L, Fields P, et al.: Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-128.
7. Easton DF, Hopper JL, Thomas DC, et al.: Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2187-2191; Author Reply 2187-2191.
8. Evans DG, Shenton A, Woodward E, et al.: Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008;8:155.
9. Fackenthal JD, Olopade OI: Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7:937-948.
10. Ford D, Easton DF, Bishop DT, et al.: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
11. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57: 1457-1462.
12. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676-689.
13. Gayther SA, Mangion J, Russell P, et al.: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-105.
14. Gayther SA, Russell P, Harrington P, et al.: The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999;65: 1021-1029.
15. Gilbert FJ, Warren RM, Kwan-Lim G, et al.: Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology 2009;252:358-368.
16. Hopper JL, Southey MC, Dite GS, et al.: Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Bio-markers Prev 1999;8:741-747.
17. King MC, Wieand S, Hale K, et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-2256.
18. Satagopan JM, Offit K, Foulkes W, et al.: The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Bio-markers Prev 2001;10:467-473.
19. Struewing JP, Hartge P, Wacholder S, et al.: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
20. Warner E, Foulkes W, Goodwin P, et al.: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-1247.
21. Satagopan JM, Boyd J, Kauff ND, et al.: Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776-3781.
22. van der Kolk DM, de Bock GH, Leegte BK, et al.: Pene-trance of breast cancer, ovarian cancer and contralat-eral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010;124:643-651.
23. Metcalfe K, Lubinski J, Lynch HT, et al.: Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010;102:1874-1878.
24. Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-419.
25. Thompson D, Easton D: Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Bio-markers Prev 2002;11:329-336.
26. Easton DF, Bishop DT, Ford D, Crockford GP: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
27. Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-1333.
28. Rhiem K, Engel C, Graeser M, et al.: The risk of con-tralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012;14:R156.
29. Metcalfe K, Gershman S, Lynch HT, et al.: Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2011;104:1384-1392.
30. Metcalfe K, Lynch HT, Ghadirian P, et al.: Contralat-eral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-2335.
31. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al.: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43:867-876.
32. Pierce LJ, Levin AM, Rebbeck TR, et al.: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437-2443.
33. Robson M, Svahn T, McCormick B, et al.: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005;103:44-51.
34. Robson ME, Chappuis PO, Satagopan J, et al.: A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004;6:R8-R17.
35. Haffty BG, Harrold E, Khan AJ, et al.: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002;359:1471-1477.
36. Verhoog LC, Brekelmans CT, Seynaeve C, et al.: Survival in hereditary breast cancer associated with ger-mline mutations of BRCA2. J Clin Oncol 1999;17: 3396-3402.
37. Verhoog LC, Brekelmans CT, Seynaeve C, et al.: Con-tralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 2000;83:384-386.
38. Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91: 1310-1316.
39. Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al.: Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:2304-2311.
40. Graeser MK, Engel C, Rhiem K, et al.: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27:5887-5892.
41. Evans DG, Moran A, Hartley R, et al.: Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. Br J Cancer 2010;102: 1091-1098.
42. Malone KE, Begg CB, Haile RW, et al.: Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010;28:2404-2410.
43. Garcia-Etienne CA, Barile M, Gentilini OD, et al.: Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol 2009;16:3380-3387.
44. Molina-Montes E, Perez-Nevot B, Pollan M, et al.: Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. Breast 2014;23:721-742.
45. Mavaddat N, Peock S, Frost D, et al.: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-822.
46. Antoniou AC, Sinilnikova OM, Simard J, et al.: RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007;81:1186-1200.
47. Antoniou AC, Spurdle AB, Sinilnikova OM, et al.: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008;82:937-948.
48. Antoniou AC, Sinilnikova OM, McGuffog L, et al.: Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009;18:4442-4456.
49. Antoniou AC, Wang X, Fredericksen ZS, et al.: A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010;42:885-892.
50. Antoniou AC, Beesley J, McGuffog L, et al.: Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010;70: 9742-9754.
51. Antoniou AC, Kuchenbaecker KB, Soucy P, et al.: Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 2012;14:R33.
52. Wang X, Pankratz VS, Fredericksen Z, et al.: Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2010;19:2886-2897.
53. Gaudet MM, Kirchhoff T, Green T, et al.: Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010;6:e1001183.
54. Friebel TM, Domchek SM, Rebbeck TR: Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju091.
55. Gail MH, Brinton LA, Byar DP, et al.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
56. Claus EB, Risch N, Thompson WD: Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-651.
57. Narod SA, Goldgar D, Cannon-Albright L, et al.: Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995;64:394-398.
58. Mazzola E, Chipman J, Cheng SC, Parmigiani G: Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 2014;23: 1689-1695.
59. Lee AJ, Cunningham AP, Kuchenbaecker KB, et al.: BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 2014;110:535-545.
60. Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-1130.
61. Amir E, Evans DG, Shenton A, et al.: Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807-814.
62. Quante AS, Whittemore AS, Shriver T, et al.: Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res 2012; 14:R144.
63. Laitman Y, Simeonov M, Keinan-Boker L, et al.: Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. Genet Res (Camb) 2013;95:174-177.
64. MacInnis RJ, Bickerstaffe A, Apicella C, et al.: Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADI-CEACentre. Br J Cancer 2013;109:1296-1301.
65. Rubino C, Arriagada R, Delaloge S, Le MG: Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 2010;102:213-219.